Myomo, Inc.
Myomo, Inc. scores highest on Nitro (67) and lowest on Price (8). Its PosiPenta is 37.35 out of 100, weaker than most similar companies.
On the Penta Grid this week, Myomo, Inc. is Grid #623 of 837 in the Healthcare sector in United States, and Grid #3,122 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Myomo, Inc. | 37.35 | 8 | 56 | 67 | 15 | 40 |
| Spectral AI, Inc. | 45.19 | 0 | 35 | 47 | 97 | 46 |
| Connect Biopharma Holdings Limited | 38.74 | 28 | 45 | 22 | 45 | 54 |
| Werewolf Therapeutics, Inc. | 39.72 | 22 | 45 | 60 | 19 | 52 |
| Kalaris Therapeutics, Inc. | 35.64 | 41 | 34 | 8 | 51 | 44 |
| Sensus Healthcare, Inc. | 50.09 | 37 | 61 | 38 | 66 | 49 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -3.53 |
| P/B ratio | 8.15 |
EEarnings
| Trailing EPS | ₹-32.20 |
| Forward EPS | ₹-20.84 |
NNitro
| Price | 113.66 |
| 52-week high | 178.54 |
| 52-week low | 57.30 |
| Fall from 52-week high | 36.3% |
TTorque
| Return on equity (ROE) | -123.76% |
| Debt-to-equity | 3.44 |
AAnchor
| Beta (price swings) | 1.58 |
| Market cap | ₹450 Cr |
| Insider holding | 9.39% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Myomo, Inc.'s PosiPenta score?
Myomo, Inc.'s PosiPenta is 37.35 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Myomo, Inc. stand on the Penta Grid?
On the Penta Grid this week, Myomo, Inc. is Grid #623 of 837 in the Healthcare sector in United States, and Grid #3,122 of 4,000 in United States.
Which PosiPenta pillar is strongest for Myomo, Inc.?
Nitro (momentum), with a score of 67 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Myomo, Inc.?
Price (valuation), with a score of 8 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.